Additional Insights
Evaluating the cellular response and fate of induced pluripotent stem cell (iPSC) advanced therapeutics and complex biologics requires a histopathology strategy built on precision. Applying proven intelligence in preclinical pathology provides the direct visual evidence needed to accelerate these next-generation therapies toward IND submission.
A standard, one-size-fits-all testing template does not exist for cell-based modalities. A science-based preclinical strategy must be tailored to the specific iPSC-derived cell type, its intended function, and the target indication. This involves designing customized immunohistochemistry (IHC) and immunofluorescence (IF) panels to answer fundamental questions about the therapeutic’s behavior post-administration.
Histopathology serves as the definitive method to verify cellular localization and persistence. Immunostaining provides the empirical data to confirm whether the iPSC-derived cells have reached the target tissue and integrated as intended, resolving biodistribution questions that cannot be answered by other methods.
Key applications of our immunostaining services for iPSC programs include:
- Confirmation of Cellular Engraftment: Visualization and quantification of therapeutic cells within the target organ.
- Assessment of Differentiation: Characterization of the cell phenotype in situ to confirm maturation into the desired lineage.
- Host Tissue Response: Evaluation of local inflammatory or immune cell infiltration surrounding the engrafted cells.
- Off-Target Biodistribution: Systematic screening of non-target tissues to identify unintended cell migration in GLP toxicology studies.
These analyses, performed under phase-appropriate GCLP or GLP conditions, generate the robust data packages required for regulatory review. This service is a component of our Preclinical | Translational Services.
